|
Market Closed -
CBOE
11:30:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 3.217 EUR | 0.00% |
|
0.00% | -40.37% |
| 09-09 | Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment | MT |
| 09-09 | Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 45.48B | |||||
| 43.68B | - | - | - | - | - |
| 43.09B | |||||
| 39.4B | |||||
| 31.91B |
- Stock Market
- Stocks
- EVT Stock
- 0IRF Stock
- Charts Evotec SE
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
